Patents by Inventor Maciej Kmieciak

Maciej Kmieciak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
    Patent number: 8741642
    Abstract: Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) bryostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: June 3, 2014
    Assignee: Virginia Commonwealth University
    Inventors: Masoud H. Manjili, Harry D. Bear, Maciej Kmieciak
  • COMPOSITION AND METHOD FOR IMMUNOLOGICAL TREATMENT OF CANCER, PREVENTION OF CANCER RECURRENCE AND METASTASIS, AND OVERCOMING IMMUNE SUPPRESOR CELLS
    Publication number: 20130309213
    Abstract: Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) byrostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 21, 2013
    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Masoud H. Manjili, Harry D. Bear, Maciej Kmieciak
  • Signatures Associated with Rejection or Recurrence of Cancer
    Publication number: 20110034347
    Abstract: Methods and tools for assessing the prognosis for patients following treatment of primary tumors are provided. The methods involve identifying immune-related genetic markers whose differential expression patterns at tumor lesions are indicative of either tumor recurrence or recurrence-free survival. The methods and tools of the invention assist physicians by providing objective decision-making tools for planning patient treatment protocols.
    Type: Application
    Filed: August 20, 2010
    Publication date: February 10, 2011
    Inventors: Masoud Manjili, Maciej Kmieciak, Harry D. Bear, Catherine I. Dumur, Michael O. Idowu